TNF and rheumatoid arthritis: After six months, lower disease activity or remission was observed more frequently in patients homozygous for the TNFR1A 36 allele than in patients homozygous for GG (52% versus 34%, p = 0.04) Additionally, at 24 weeks of treatment, the subgroup of RA patients homozygous for the TNFA-856T variant had a significantly lower DAS28 score compared to RA patients carrying the C allele (p = 0.045).